WebDec 18, 2024 · Richter treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, plasma cell leukemia and … WebMultiple Myeloma expert Santhosh K Sadavish MD, discusses the importance of targeted therapies for these patients and how CAR T-cell therapy has changed the outcomes of patients who relapse after multiple lines of therapy. ... Dr Joshua Richter explains which patients with multiple myeloma are most suitable for triplet combination therapies ...
Multiple Myeloma Treatment and Immunotherapy Advances
WebJul 1, 2024 · In a HealthDay Now interview, Dr. Joshua Richter, assistant professor of medicine at the Tisch Cancer Institute, shared highlights from the European Hematology Association's 2024 meeting and discussed the progress made in treating multiple myeloma and other blood-based cancers. WebJul 31, 2024 · Dr. Joshua Richter, Assistant Professor of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine joins … dr riley urology cumberland md
Dr. Joshua Richter, Hematology New York, NY WebMD
WebJun 2, 2024 · Multiple Myeloma Approvals Likely in 2024 Dr. Richter expects to see FDA approvals of bispecific antibodies or agents as early as 2024. These are antibody molecules with two arms. One arm targets BCMA, the other targets CD3, a marker on the T-cells. WebDr. Richter specializes in multiple myeloma as well as other plasma cell dyscrasias such as amyloidosis and Waldenstrom’s macroglobulinemia. His clinical research interests focus on multi-functional antibodies and precision medicine. Last modified: July 29, 2024 Authored Items What do you see for the future of myeloma treatment? Joshua Richter, MD WebDec 9, 2024 · Dr Richter’s extensive research record covers multiple myeloma, light chain amyloidosis, plasma cell leukemia and Waldenstrom’s macroglobulinemia. He has a strong interest in novel immunotherapies -particularly multifunctional antibodies- and early phase clinical trials, which he has had significant involvement in, in the myeloma field. dr rima chowdhury